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Abstract Venous thromboembolism (VTE) is a common
complication of hematopoietic stem cell transplantation
(HSCT). Graft-versus-host disease (GVHD) is another com-
plication of HSCT that may modify the risk of VTE. Our
objective was to explore the incidence of VTE (deep venous
thrombosis and pulmonary embolism) following HSCTand to
evaluate its association with GVHD. A comprehensive search
of Medline In-Process & Other Non-Indexed Citations,
MEDLINE, EMBASE, Cochrane Central Register of
Controlled Trials, and Scopus was conducted to search for
both retrospective and prospective HSCT studies which had
reported VTE. Random-effects meta-analysis was used to
pool incidence rates. We included 17 studies reporting on
allogeneic- and 10 on autologous-HSCT; enrolling 6693 pa-
tients; of which 5 were randomized. The overall incidence of
VTE after HSCT was 5 % (4–7 %). Incidence in allogeneic-
HSCTwas 4% (2–6%) and in autologous-HSCTwas 4% (1–
15 %). Eleven and nine studies reported data on acute and
chronic GVHD, respectively. The incidence of VTE in chron-
ic GVHD was 35 % (20–54 %), whereas in acute GVHD it
was 47 % (32–62 %). Based on the results of this meta-anal-
ysis, VTE is a fairly common complication after HSCT, em-
phasizing the importance of assimilating guidelines for both
treatment and prophylaxis in this patient population.
Keywords Venous thromboembolism . Deep venous
thrombosis . Pulmonary embolism . Bonemarrow
transplantation . Hematopoietic stem cell transplantation .
Complication
Introduction
Hematopoietic stem cell transplantation (HSCT) is the stan-
dard of care in a variety of benign and malignant hematologic
disorders and is being employed at an increasing frequency in
the last two decades [1].
Recent studies have recognized that thromboembolic com-
plications, such as venous thromboembolism (VTE), are a
serious cause of morbidity and mortality in HSCT patients
[2–5]. Recipients of HSCT are prone to develop VTE due to
several risk factors. These include underlying cancer, indwell-
ing central venous catheters, hospital admission leading to
prolonged periods of immobility, cytotoxic chemotherapy or
radiation therapy as preparative regimens, infections, and
graft-versus-host disease (GVHD) [2, 3].
Hepatic sinusoidal obstruction syndrome (SOS) and throm-
botic microangiopathy (TMA) are well-known thrombotic
complications following HSCT [6, 7]. SOS is usually related
to high-dose cytotoxic chemotherapy, as is used in
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myeloablative conditioning regimens [8], while TMA can be
associated with the use of calcineurin inhibitors, sirolimus,
and rarely GVHD [9, 10]. However, the incidence and risk
factors for VTE following HSCT are not well defined. HSCT
patients are also at an increased risk of bleeding following
transplant [1, 2], which has been associated with a shorter
survival in such patients [11]. Consequently, clinicians face a
difficult choice regarding VTE prophylaxis in HSCT patients
and lack sufficient information to make informed decisions.
There is little information regarding appropriate therapeutic
and prophylactic approaches to VTE in this complex patient
population. The incidence of VTE in HSCT has been reported
with variable frequencies, ranging from 0.5 % to as high as
23.5 % [12, 13].
Given the increasing recognition of the endothelial form of
GVHD resulting in an increase in cardiovascular complica-
tions, we hypothesized that VTE incidence would be height-
ened in patients suffering from GVHD [14].
Thus, we performed a systematic review and meta-analysis
to assess the overall incidence of VTE following HSCT, in-
cluding deep venous thrombosis (DVT) and pulmonary em-
bolism (PE). We also assessed the likelihood of VTE follow-
ing allogeneic-HSCT and autologous-HSCT, separately.
Materials and methods
This systematic review and meta-analysis is reported follow-
ing criteria set by the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) statement (http://
www.prisma-statement.org) [15].
Eligibility criteria
Types of studiesWe searched literature databases for clinical
trials as well as prospective and retrospective observational
studies with patients receiving allogeneic- and/or autolo-
gous-HSCT. Studies reporting the outcome and complications
in these patients (venous thrombosis alone or in addition to
other complications of HSCT) were included.
Types of participants We included all patients receiving ei-
ther allogeneic- or autologous-HSCT for treatment. There
were no restrictions in regards to age, ethnicity, gender, or
underlying disease for which HSCTwas being performed.
Types of outcome measures The primary outcome was the
development of thrombosis in the venous system after the
infusion of hematopoietic stem cells following pre-transplant
conditioning chemotherapy. This included upper and lower
extremity DVT, PE, thrombosis in veins related to internal
organs (e.g., hepatic vein, internal jugular vein, etc.), and
thrombosis associated with indwelling catheters used during
the transplantation process.
Exclusion criteria The exclusion criteria are as follows: (1)
case reports, case series and studies with patient population of
<5 (to avoid statistical skewing of the results); (2) studies
involving patients that do not represent typical HSCT patients
(e.g., involving the use of erythropoiesis-stimulating agents,
immunotherapy, or other interventions that are not typically
used simultaneously with HSCT, immunotherapy with subcu-
taneous IL-2 after transplant, multiple myeloma patients who
had relapsed disease after getting allogeneic-HSCT and were
getting lenalidomide as salvage treatment, multiple myeloma
patients getting thalidomide immediately after getting auto-
transplant, etc.); (3) review articles and studies in which pa-
tients who developed VTE after HSCTwere not quantifiable;
(4) studies describing thrombotic complications other than
VTE, e.g., SOS or arterial thrombosis; (5) autopsy studies
reporting VTE in HSCT patients (to maintain uniformity);
(6) studies reporting only catheter-related thrombosis; and
(7) studies describing VTE in patients prior to HSCT or in
non-HSCT patients.
Information sources and search strategy
A comprehensive search of several databases from each data-
base’s earliest inception to June 2014, in any language, was
conducted. The databases included Medline In-Process &
Other Non-Indexed Citations, MEDLINE, EMBASE,
Cochrane Central Register of Controlled Trials, and Scopus.
The search strategy was designed and conducted by an expe-
rienced librarian with input from the study’s principal investi-
gator. Controlled vocabulary supplemented with keywords
was used to search for studies of VTE in bone marrow trans-
plantation. The actual strategy is available in Appendix.
Study selection and data collection
Two investigators (SKH andMFZ) independently screened all
studies by reviewing titles and abstracts. Potentially relevant
studies were retrieved as full text articles. All full text articles
were screened again in duplicate following the same inclusion
criteria. In case of any disagreement in regards to inclusion of
a study, this was discussed with a third investigator (MSP). All
studies were critically appraised in regards to relevance and
validity for inclusion in this systematic review or for further
exclusion. Data were collected for the variables described in
data items below and recorded in an excel sheet.
The following data were extracted from each study: author,
year of publication, total study population, indication for
HSCT, type of HSCT (allogeneic vs. autologous), total inci-
dence of VTE, and type of VTE (PE, DVT, catheter-related
thrombosis, etc). Our primary outcome was the occurrence of
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first VTE. We defined VTE as thrombosis involving the deep
veins of any extremity detected by any standard radiologic
means.
Study quality appraisal (risk of bias)
The Cochrane Collaboration’s tool for assessing risk of bias
was used for quality appraisal of randomized studies [16]
(Table 1). We used the Newcastle-Ottawa Scale for assessing
the quality of non-randomized studies [21] (Table 2).
Statistical analysis
Statistical analysis was performed using Comprehensive
Meta-Analysis Version 2.0 (Englewood, NJ). We used the
random-effects model to pool outcomes across studies due
to anticipated heterogeneity. Outcome measure was evaluated
as cumulative incidence (i.e., event rate). Subgroup analyses
were undertaken based on (a) allogeneic vs. autologous trans-
plants, (b) presence of GVHD, and (c) type of GVHD, i.e.,
acute vs. chronic.
Results
Electronic search yielded 755 articles (Fig. 1) out of which
only 146 articles were relevant to the study question. Many
studies reported patients that developed VTE after HSCT, but
the incidence could not be quantified so they were excluded.
Thrombotic complications other than VTE, e.g., SOS or arte-
rial thrombosis (n=13), were excluded. However, if they had
also reported VTE incidences, then the VTE numbers were
included in the analysis. Studies reporting VTE in HSCT pa-
tients prior to stem cell infusion or in non-HSCT patients
(n=18) were also excluded. Some studies (n=4) had reported
postmortem finding of VTE and they were excluded. Only 23
studies fulfilled the strict inclusion criteria and were included
in the statistical analysis. The randomized trials and the obser-
vational studies had moderate risk of bias, overall.
Twelve studies in allogeneic-HSCT yielded an incidence
rate of 4 % (95 % CI 2–6 %) with significant heterogeneity
(I2 =80). Six studies in autologous-HSCT yielded a similar
incident rate of 4 % (95 % CI 1–15 %) with significant het-
erogeneity (I2 = 89). Five studies with patients undergoing
both autologous- and allogeneic-HSCT yielded an incident
rate of 6 % (4–9 %) with significant heterogeneity (I2 =93).
There was no significant difference in the incidence of VTE
between allogeneic- and autologous-HSCT (p=0.94). Overall
VTE incidence from 23 studies was 5 % (4–7 %).
When we analyzed the GVHD data with respect to VTE
incidence, 11 studies reported data on acute GVHD in which
the incidence of VTEwas found to be very high at 47% (95%
CI 32–62 %) with significant heterogeneity (I2 = 98). The
incidence of VTE in chronic GVHD from nine studies was
also found to be very high at 35 % (95 % CI 20–54 %) indi-
cating a possibly strong association with GVHD.
Discussion
We conducted a systematic review and meta-analysis of stud-
ies evaluating VTE after HSCT. We found that VTE is fairly
common with an overall incidence of 5 %. In patients with
GVHD, the risk was much higher. The certainty in these esti-
mates is limited due to the presence of heterogeneity that
remained unexplained and likely reflects differences in out-
come surveillance and ascertainment as well as heterogeneity
in the population’s other risk factors for VTE.
Clinically apparent VTE occurs in up to 10 % of patients
with active cancer [33], and many algorithms exist which can
predict the risk of cancer thrombosis among which the
Khorana model is regarded as the gold standard [34]. No such
model exists for HSCT patients due to the absence of data on
the risks and outcomes of VTE in this population.
Theoretically, HSCT survivors who do not have any relapses
of cancer should not have an elevated risk of VTE unless other
known risk factors are present or new factors are acquired. A
well-known non-relapse risk factor of VTE in HSCT patients
is the presence of central venous catheters which are inserted
in majority of the patients undergoing HSCT [2, 3, 32]. Some
studies have indicated HSCT-associated VTE incidences of
0.5 % [13], whereas other studies have indicated an incidence
as high as 23.5 % [12] post-HSCT. To delineate the totality of
evidence of VTE risks and outcomes in HSCT population, we
undertook this meta-analysis.
Our meta-analysis of both observational studies and ran-
domized clinical trials showed that the overall risk of VTE
post-HSCT was similar to that described by Gerber et al. [2].
We found no significant difference between allogeneic- and
autologous-HSCT for VTE occurrence. However, when we
undertook the analysis of GVHD with VTE, a significantly
high risk of VTE was observed both in acute and chronic
GVHD of 47 and 35 %, respectively.
Besides being the first meta-analysis on the risk of VTE in
HSCT patients, this analysis separates out the risk of provoked
(line associated) vs. unprovoked VTE. We did a comprehen-
sive qualitative assessment of the prospective randomized
studies included in our meta-analysis using Cochrane
Collaboration’s tool for assessing risk of bias. Our strict selec-
tion criteria excluded VTE post-HSCT in the patients with
pre-existing hypercoagulable states. We did the analysis based
on both chronic and acute GVHD for VTE incidence to ascer-
tain a possible association of GVHD with VTE.
In 1856, Virchow proposed a triad of causes for venous
thrombosis, postulating that stasis, changes in the vessel wall,
or changes in the blood could lead to thrombosis. GVHD can
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cause significant endothelial injury which can result in a mul-
titude of inflammatory cascades resulting in cytokine storm
especially in the setting of acute GVHD [35, 36]. The role of
donor T cells post-allogeneic-HSCT adhering to endothelium
in the vasculature as the first potential extensive area of con-
tact with new host antigens is well established [37, 38]. For
chronic GVHD which exhibits a unique pathogenesis distinct
from acute GVHD [39], current evidence indicates that, in
addition to damage to targeted epithelia, changes to the mi-
crovascular endothelium play a role in the pathogenesis of
chronic GVHD [40–42]. It is well known that long-term sur-
vivors after allogeneic-HSCT are at a high risk for premature
arterial vascular disease [43–45]. The common endothelial
syndromes that HSCT patients suffer from include TMA,
SOS, engraftment syndrome, and capillary leak syndrome
[6, 7, 46–48]. These early transplant-related endothelial dam-
age syndromes result mainly due to direct cellular toxicity, a
potent procoagulant condition, and heightened inflammatory
responses manifested by cytokine storms post-HSCT. Thus,
adequate mechanisms are well documented that provide a ra-
tionale for the biologic plausibility of a high thrombotic state
in GVHD.
Since the incidence of VTE was reported as an adverse
event in most of the studies and was not the primary outcome
for most of the clinical trials, a definite causal link between
GVHD and VTE cannot be established. Many other residual
confounding factors may be present as the studies did not
report all potential risk factors for GVHD.
Although we removed the studies (and/or patients in indi-
vidualized studies) with catheter-related GVHD, it is possible
that some studies did not report presence or absence of central
catheters since many patients at the time of HSCT and post-
HSCT for few weeks or months still have catheters present,
thus potentially confounding the association of VTE with
acute GVHD. In chronic GVHD, although not reported in
most studies, it is unlikely that majority of patients had central
catheters, unless required for a treatment modality such as
photopheresis. A VTE incidence of 35 % in chronic GVHD
is alarming and suggests the need for further definitive studies
to prove (or disprove) a causal link of GVHD with VTE.
However, one must consider the possibility that these results
may overestimate the incidence and link of VTE with GVHD.
The details of GVHD were not available from each study;
however, in all studies where the grades of GVHD were men-
tioned, they were compared. Incidental findings of VTE may
also overestimate its incidence in HSCT patients, who usually
undergo various investigations and extensive follow-up tests
for various indications. The same incidence may not be true in
patients with hematologic disorders being treated with non-
transplant modalities. Another limitation in the present meta-
analysis is that patient level (individual level) data was not
available from each study. In addition, the included studies
were inconsistent in reporting symptomatic VTE against
asymptomatic VTE. While symptomatic VTE is a clear indi-
cation for therapeutic interventions, guidelines for the
approach/treatment of asymptomatic VTE are not defined
and open for discussion. Since incidental/asymptomatic
VTE findings are common in HSCT patients considering the
high rate of diagnostic procedures performed in this patient
population, it is imperative to develop such protocols to guide
Fig. 1 Search and inclusion of
selected studies
1462 Ann Hematol (2016) 95:1457–1464
clinical practice. Exploring the incidence of symptomatic
against asymptomatic VTE also represents a potential topic
of future research interest.
It is evident from this meta-analysis that patients undergo-
ing HSCT are at an elevated risk of both PE and DVT.
Currently, the practice of DVT prophylaxis varies significant-
ly between institutions as some transplant centers routinely
provide anticoagulants post-HSCT for the prevention of
SOS. Additionally, in autologous-HSCTs, a special consider-
ation may be post-HSCT immuno-modulatory drug therapy
which may be a risk factor for VTE post-HSCT. Lastly, the
potential association of immobility due to severe chronic
GVHD and VTE needs to be further evaluated in long-term
studies.. Definitive prospective trials are also needed to con-
firm the absolute and relative risks of VTE in HSCT patients
and to prove the causal relationship between GVHD andVTE.
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